Hepatitis C: Treatment of difficult to treat patients

doi:10.4254/wjh.v7.i15.1953

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 15

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8822)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

543

WORD

230

HTML

3276

Figures (1-2)

227

Tables (1-3)

223

Sum=4499

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

554

Download

1233

Sum=1787

Publishing Process of This Article

Item

Count

Browse

928

Download

1608

Sum=2536

Jul 28, 2015 (publication date) through Nov 29, 2024

Times Cited of This Article

Times Cited (21)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Jul 28, 2015; 7(15): 1953-1963
Published online Jul 28, 2015. doi: 10.4254/wjh.v7.i15.1953

Table 2 Currently available Food and Drug Administration approved pharmaceuticals for treatment of hepatitis C virus

Approved treatments for hepatitis C
Brand name	Generic names	Manufacturer name
Sovaldi	SOF	Gilead Sciences
Olysio	SIM	Janssen
Incivek	TVR	Vertex
Victrelis	BOC	Merck and Co.
Pegasys	Peg-IFN	Roche
CoPegus	RBV	Roche
Pegintron	Peg-IFN alpha-2b	Schering
Intron A	IFN alpha-2b	Schering
Rebetol	RBV	Schering
Roferon	IFN alpha-2a	Roche
Infergen	IFN aphacon-1	Three Rivers Pharma

Adapted from http://www.fda.gov/. SOF: Sofosbuvir; SIM: Simeprevir; TVR: Telaprevir; BOC: Boceprevir; RBV: Ribavirin; Peg-IFN: Pegylated interferon.

Citation: Hilgenfeldt EG, Schlachterman A, Firpi RJ. Hepatitis C: Treatment of difficult to treat patients. World J Hepatol 2015; 7(15): 1953-1963
URL: https://www.wjgnet.com/1948-5182/full/v7/i15/1953.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i15.1953